Tacconi moves back to Merck to head investigational obesity drug

Share this article:
Merck has brought back consumer marketing guru Len Tacconi to serve as global brand leader for its lead investigational component for obesity, taranabant.
 
Tacconi, who first joined Merck in 1996 to build its consumer marketing capability, left the company in September, 2006 to become president of Discovery Health Media Enterprises. He returns to a familiar category, having cut his teeth heading North American marketing for Weight Watchers before joining Merck.

In his previous stint with the pharma giant, Tacconi orchestrated successful consumer campaigns for mega-blockbusters like Singulair, Zocor and Vioxx before heading the firm's corporate reputation efforts in the wake of the Vioxx withdrawal, launching Merck's first-ever corporate advertising with the “Where patients come first” campaign in June 2005. Along the way, he also led the company's physician marketing, business technology and publishing functions.  

At Discovery, he was charged with the strategic, operational and financial management of the company's health media platform, including the Discovery Health Channel, FitTV, discoveryhealth.com, CME and a video-on-demand service, Discovery Health On-Call. Those duties will now fall to Discovery Health Media general manager/EVP Carole Tomko, who previously served as EVP of Discovery's internal production unit, Discovery Studios.

Taranabant, a cannabinoid-1 (CB-1) receptor inverse agonist in Phase III clinical trials, has a mechanism of action similar to that of Sanofi-Aventis' rimonabant. Sanofi-Aventis withdrew its NDA for the drug in June after an FDA advisory committee recommended against approving it due to concerns over possible psychiatric side effects. Pfizer is also working on a cannabinoid receptor, dubbed CP-945598.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...